LUYE PHARMA GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.99 HKD | +0.67% |
|
-1.97% | -19.84% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 17,061 | 9,872 | 10,273 | 11,474 | 12,753 | 10,412 | - | - |
| Enterprise Value (EV) 1 | 19,939 | 15,881 | 16,937 | 15,546 | 12,753 | 13,004 | 12,821 | 12,348 |
| P/E ratio | 11.4 x | 13.7 x | -74.4 x | 18.6 x | 23.7 x | 16.2 x | 12.2 x | 9.91 x |
| Yield | 2.17% | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.68 x | 1.78 x | 1.98 x | 1.92 x | 2.08 x | 1.52 x | 1.33 x | 1.18 x |
| EV / Revenue | 3.14 x | 2.87 x | 3.26 x | 2.6 x | 2.08 x | 1.9 x | 1.64 x | 1.39 x |
| EV / EBITDA | 7.81 x | 8.46 x | 18.7 x | 8.58 x | 6.14 x | 7.52 x | 6.52 x | 5.54 x |
| EV / FCF | 25,743,540 x | 46,621,206 x | -45,307,565 x | 31,699,228 x | - | - | - | - |
| FCF Yield | 0% | 0% | -0% | 0% | - | - | - | - |
| Price to Book | 1.81 x | 1.23 x | 1.18 x | 1.11 x | - | 0.74 x | 0.7 x | 0.65 x |
| Nbr of stocks (in thousands) | 3,268,965 | 3,248,965 | 3,541,372 | 3,549,671 | 3,761,671 | 3,761,671 | - | - |
| Reference price 2 | 5.219 | 3.038 | 2.901 | 3.232 | 3.390 | 2.768 | 2.768 | 2.768 |
| Announcement Date | 3/26/20 | 3/31/21 | 3/29/22 | 3/29/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,358 | 5,540 | 5,200 | 5,982 | 6,143 | 6,831 | 7,811 | 8,859 |
| EBITDA 1 | 2,553 | 1,877 | 906.9 | 1,813 | 2,077 | 1,730 | 1,967 | 2,230 |
| EBIT 1 | 1,729 | 961.2 | -6.49 | 747.6 | 872.9 | 1,144 | 1,342 | 1,564 |
| Operating Margin | 27.2% | 17.35% | -0.12% | 12.5% | 14.21% | 16.75% | 17.19% | 17.66% |
| Earnings before Tax (EBT) 1 | 1,772 | 942.2 | -74.56 | 669.8 | 700.1 | 799.6 | 1,046 | 1,294 |
| Net income 1 | 1,469 | 706.6 | -134.4 | 604.8 | 532.6 | 676.5 | 964.9 | 1,189 |
| Net margin | 23.1% | 12.76% | -2.58% | 10.11% | 8.67% | 9.9% | 12.35% | 13.42% |
| EPS 2 | 0.4584 | 0.2212 | -0.0390 | 0.1738 | 0.1429 | 0.1709 | 0.2270 | 0.2794 |
| Free Cash Flow | 774.5 | 340.6 | -373.8 | 490.4 | - | - | - | - |
| FCF margin | 12.18% | 6.15% | -7.19% | 8.2% | - | - | - | - |
| FCF Conversion (EBITDA) | 30.34% | 18.15% | - | 27.05% | - | - | - | - |
| FCF Conversion (Net income) | 52.74% | 48.21% | - | 81.09% | - | - | - | - |
| Dividend per Share 2 | 0.1130 | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/31/21 | 3/29/22 | 3/29/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,227 | 2,962 | 2,577 | 2,952 | 2,249 | 2,851 | 3,131 | 2,904 | 3,239 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 521.8 | 589.5 | 300.6 | - | -294.8 |
| Operating Margin | - | - | - | - | 23.2% | 20.68% | 9.6% | - | -9.1% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.2202 | 0.1686 | 0.0526 | 0.1129 | -0.1519 | 0.0854 | 0.0884 | 0.0406 | 0.1023 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 8/27/20 | 3/31/21 | 8/29/21 | 3/29/22 | 8/29/22 | 3/29/23 | 8/29/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,878 | 6,009 | 6,665 | 4,072 | - | 2,592 | 2,410 | 1,937 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.127 x | 3.201 x | 7.349 x | 2.246 x | - | 1.499 x | 1.225 x | 0.8686 x |
| Free Cash Flow | 775 | 341 | -374 | 490 | - | - | - | - |
| ROE (net income / shareholders' equity) | 17.2% | 10.9% | -1.64% | 6.48% | - | 5.01% | 6.15% | 7.14% |
| ROA (Net income/ Total Assets) | 7.97% | 4.56% | 2.03% | - | - | - | - | - |
| Assets 1 | 18,426 | 15,497 | -6,614 | - | - | - | - | - |
| Book Value Per Share 2 | 2.880 | 2.480 | 2.460 | 2.920 | - | 3.720 | 3.970 | 4.260 |
| Cash Flow per Share | 0.5400 | 0.3200 | 0.0500 | 0.4800 | - | - | - | - |
| Capex | 970 | 693 | 556 | 1,163 | - | - | - | - |
| Capex / Sales | 15.26% | 12.51% | 10.7% | 19.45% | - | - | - | - |
| Announcement Date | 3/26/20 | 3/31/21 | 3/29/22 | 3/29/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.768
CNY
Average target price
2.822
CNY
Spread / Average Target
+1.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.84% | 1.44B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 2186 Stock
- Financials Luye Pharma Group Ltd.
